Your browser doesn't support javascript.
loading
Residual neuromuscular blockade and late neuromuscular blockade at the post-anesthetic recovery unit: prospective cohort study.
Gonçalves, Pedro Marcos Silva E; Vieira, Alexandra de Vasconcelos; Silva, Claudia Helena Ribeiro da; Gomez, Renato Santiago.
  • Gonçalves PMSE; Universidade Federal de Minas Gerais (UFMG), Faculdade de Medicina, Programa de Pós-Graduação em Ciências Aplicadas à Cirurgia e à Oftalmologia, Belo Horizonte, MG, Brasil. Electronic address: pedro.marcoss@yahoo.com.br.
  • Vieira AV; Hospital Unimed BH - Unidade Contorno, Serviço de Anestesiologia, Belo Horizonte, MG, Brasil.
  • Silva CHRD; Hospital Unimed BH - Unidade Contorno, Serviço de Anestesiologia, Belo Horizonte, MG, Brasil.
  • Gomez RS; Universidade Federal de Minas Gerais (UFMG), Faculdade de Medicina, Programa de Pós-Graduação em Ciências Aplicadas à Cirurgia e à Oftalmologia, Belo Horizonte, MG, Brasil.
Braz J Anesthesiol ; 71(1): 38-43, 2021.
Article en En | MEDLINE | ID: mdl-33712250
ABSTRACT
INTRODUCTION AND

OBJECTIVES:

The use of neuromuscular blockers during surgery represented a landmark for anesthesiology. However, their use can prompt residual Neuromuscular Blockade (RNMB) and objective monitoring of neuromuscular function is crucial to warrant the recovery of muscle strength. The present study aimed to estimate the incidence of RNMB and late Neuromuscular Blockade (LNMB) at the Post-Anesthetic Recovery Unit (PACU).

METHOD:

The study included 85 patients, 43 of which received cisatracurium and 42 of which, rocuronium. The depth of the Neuromuscular Blockade (NMB) was assessed by Train Of Four (TOF). NMB reversal was performed with the administration of neostigmine and atropine.RNMB was defined when a patient presented TOF below 90% at the PACU.

RESULTS:

RNMB at the PACU was diagnosed in 39.5% and 40.5% of the patients receiving cisatracurium and rocuronium, respectively (p = 1.0). LNMB at the PACU was found in 32.6% and 16.7% of the patients receiving cisatracurium and rocuronium, respectively (p = 0.131).

CONCLUSIONS:

The incidence ofRNMB remains significant despite the use of intermediate-acting neuromuscular blockers and reversal agents. There was no statistically significant difference in the incidence of RNMB or LNMB in patients receiving cisatracurium or rocuronium. The use of objective NMB monitoring is effective for the diagnosis of RNMB, as well as for treatment management.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Bloqueo Neuromuscular / Retraso en el Despertar Posanestésico / Anestésicos Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Bloqueo Neuromuscular / Retraso en el Despertar Posanestésico / Anestésicos Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article